GlaxoSmithKline plc  

(Public, LON:GSK)   Watch this stock  
Find more results for GSK
-3.65 (-0.22%)
Aug 24 - Close
LON real-time data - Disclaimer
Currency in GBX unless noted
Range 1,652.12 - 1,676.18
52 week 1,227.50 - 1,716.50
Open 1,661.00
Vol / Avg. 4.24M/7.82M
Mkt cap 80.84B*
P/E 3,146.77
Div/yield 19.00*
EPS 0.01*
Shares 4.87B
Beta     -
Inst. own     -
Oct 26, 2016
Q3 2016 GlaxoSmithKline PLC Earnings Release Add to calendar
Sep 7, 2016
GlaxoSmithKline PLC at Wells Fargo Securities Healthcare Conference Add to calendar
Sep 2, 2016
GlaxoSmithKline PLC Corporate Analyst Meeting - 2:00PM GMT+1 - Add to calendar
Jul 27, 2016
Q2 2016 GlaxoSmithKline PLC Earnings Call
Jul 27, 2016
Q2 2016 GlaxoSmithKline PLC Earnings Release
Jun 8, 2016
GlaxoSmithKline PLC at Goldman Sachs Global Healthcare Conference

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin -7.53% 35.00%
Operating margin -2.31% 46.67%
EBITD margin - 32.04%
Return on average assets -3.52% 17.79%
Return on average equity -103.18% 179.63%
Employees 101,192 -
CDP Score - 100 B


980 Great West Road
United Kingdom - Map
+44-20-80475000 (Phone)
+44-20-80477807 (Fax)

Website links

External links

Analyst Estimates - BusinessWeek
Options - MarketWatch
Director Dealings - Yahoo Finance


GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company's segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare. The Pharmaceuticals business develops and makes medicines to treat a range of acute and chronic diseases. The Vaccines business develops, produces and distributes over 1.9 million vaccines every day to people across the world. The Consumer Healthcare business develops and markets products in various categories, such as Wellness, Oral health, Nutrition and Skin health. The Pharmaceuticals Research and Development (R&D) focuses on the discovery and development in various areas of research, which include human immunodeficiency virus (HIV) and infectious diseases, oncology, immuno-inflammation, respiratory and rare diseases.

Officers and directors

Andrew Philip Witty Chief Executive Officer, Executive Director
Age: 50
Simon Dingemans Chief Financial Officer, Executive Director
Age: 51
Moncef Slaoui Chairman - Global Vaccines, Executive Director
Age: 55
Roger Connor President - Global Manufacturing & Supply
Abbas Hussain President, Global Pharmaceuticals
Shah Abbas Hussain President - Europe, Japan & EMAP
Age: 49
Patrick Vallance President - Pharmaceuticals R&D
Emma Walmsley President - Consumer Healthcare Worldwide
Daniel Troy Senior Vice President, General Counsel
Claire Thomas Senior Vice President - Human Resources